V5 Ultimate
Guide

Pharmaceutical GMP readiness in Brazil

Brazil's ANVISA (Agência Nacional de Vigilância Sanitária) regulates medicines under Law 6.360/1976 and a series of Resolutions of the Collegiate Board (RDCs). The current GMP regulation is RDC 658/2022 (in force from 2022, replacing RDC 301/2019), aligned with PIC/S GMP — Brazil became a PIC/S member in 2021. Every manufacturing site (domestic or foreign) supplying Brazil needs a Certificate of Good Manufacturing Practices (CBPF) from ANVISA. Serialization is mandatory under the Sistema Nacional de Controle de Medicamentos (SNCM). This guide covers the Brazil-specific layer.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

ANVISA is the federal authority. RDC 658/2022 sets GMP for human medicines and biologicals; RDC 654/2022 covers active ingredients (DIFAs); RDC 665/2022 covers IMPs. Brazil joined PIC/S in 2021 — RDC 658 is essentially PE 009 with Brazilian terminology. ANVISA inspects and issues CBPFs on a 2-year cycle.

Registration and CBPF

Marketing requires a registration (registro sanitário) held by a Brazilian legal entity. Each manufacturing site listed on the registration needs a current CBPF; ANVISA inspects foreign sites on a queue (historically 18–36 months) — this is a primary bottleneck for new entrants. CBPF is granted by product class (sterile, non-sterile, biologicals, etc.).

SNCM serialization and dossier language

SNCM requires unique-identifier serialization (GTIN + serial + batch + expiry) on all human medicines, with reporting through ANVISA's national hub at each supply-chain event. Dossiers and labelling must be in Portuguese; technical content may be supported by English data but key sections need certified translation.

Inspection style and common findings

ANVISA inspections follow PIC/S classification (critical/major/other). Brazilian inspectors are detail-driven; common findings: stability program adequacy for tropical zones (Zone IVb), data integrity, supplier qualification of imported APIs (including DIFAs registration), and Annex 1 contamination control.

A 90–180 day Brazil readiness path

Days 0–30: identify the Brazilian registration holder and map products to CBPF scope. Days 31–90: align documentation to RDC 658/2022, complete Portuguese labelling and IFU, and verify SNCM serialization onboarding. Days 91–180: submit CBPF inspection request; meanwhile run mock inspection and close ICH Q1A stability gaps for Zone IVb.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

How long is the CBPF inspection queue?
Historically 18–36 months for foreign sites, though it has shortened recently and PIC/S reliance is being expanded. Plan early — CBPF is the long pole for Brazil market entry.
What is a DIFA?
Dossiê de Insumo Farmacêutico Ativo — an API/active master file registered with ANVISA. Each registered medicinal product must reference an approved DIFA for each active ingredient.
What stability zone applies to Brazil?
Zone IVb (30 °C / 75% RH) for most of the country. Stability programs designed only for Zone II (25 °C / 60% RH) are a common reason for delays.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Spot something off? .